CR Bard losing jobs with a $20 million charge

In an effort to cut costs, C.R. Bard, which creates catheters and other small devices, will cut jobs and take a $20 million hit to its fourth quarter earnings. The company has not released how many jobs it expects to slash.

The company disclosed the $20 million charge in a SEC filing, saying that the majority of the hit will come from severance packages. It will also restructure its administration, manufacturing and sales to relieve pressure on its profits and will issue $750 million in senior unsecured notes as a potential repurchase program for its stock.

- read the Bloomberg coverage
- and here's the Wall Street Journal article

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.